Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Accumulated Expenses: 2019-2025

Historic Accumulated Expenses for Revolution Medicines (RVMD) over the last 6 years, with Sep 2025 value amounting to $256.5 million.

  • Revolution Medicines' Accumulated Expenses rose 228.81% to $256.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $256.5 million, marking a year-over-year increase of 228.81%. This contributed to the annual value of $96.6 million for FY2024, which is 29.35% up from last year.
  • As of Q3 2025, Revolution Medicines' Accumulated Expenses stood at $256.5 million, which was up 4.66% from $245.1 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Accumulated Expenses peaked at $256.5 million during Q3 2025, and registered a low of $20.4 million during Q1 2021.
  • Its 3-year average for Accumulated Expenses is $99.1 million, with a median of $74.7 million in 2023.
  • Data for Revolution Medicines' Accumulated Expenses shows a peak YoY soared of 262.11% (in 2025) over the last 5 years.
  • Revolution Medicines' Accumulated Expenses (Quarterly) stood at $27.7 million in 2021, then rose by 6.22% to $29.4 million in 2022, then spiked by 153.66% to $74.7 million in 2023, then rose by 29.35% to $96.6 million in 2024, then skyrocketed by 228.81% to $256.5 million in 2025.
  • Its last three reported values are $256.5 million in Q3 2025, $245.1 million for Q2 2025, and $98.1 million during Q1 2025.